Mercy BioAnalytics
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $119M
Investors
- 13
About Mercy BioAnalytics
Based in Massachusetts, US, and founded in 2018 by Joseph Sedlak, and Paul Blavin, Mercy BioAnalytics, Inc. operates as a biotech company dedicated to the early detection of cancer through the use of extracellular vesicles (EVs) found in the blood. In September 2025, Mercy BioAnalytics, Inc. Mercy BioAnalytics, Inc. developed a blood-based assay called the Halo test, for the early detection of various types of cancer, including ovarian and lung cancer. It analyzes single extracellular vesicles (EVs) and utilizes the surface proteins that carry information about their tumor cell of origin to achieve sensitivity and specificity. The platform utilizes biomarker co-localization to interrogate highly abundant, blood-based extracellular vesicles. The abundance of extracellular vesicles in circulation enables the Mercy Halo test to be run on a very small volume of serum or plasma with a PCR-based read-out.
Who invested in Mercy BioAnalytics
13 investors across 2 rounds
See all investors in Mercy BioAnalytics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mercy BioAnalytics
Who invested in Mercy BioAnalytics?
Mercy BioAnalytics has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mercy BioAnalytics raised?
Mercy BioAnalytics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Mercy BioAnalytics last raise money?
Mercy BioAnalytics's most recent round on record is a Series B, in Sep 2025.
What does Mercy BioAnalytics do?
Based in Massachusetts, US, and founded in 2018 by Joseph Sedlak, and Paul Blavin, Mercy BioAnalytics, Inc.
Where is Mercy BioAnalytics headquartered?
Mercy BioAnalytics is headquartered in Waltham, US.
Which VCs invest in companies like Mercy BioAnalytics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Mercy BioAnalytics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Mercy BioAnalytics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.